title: Pharmacokinetics of enrofloxacin and marbofloxacin in Japanese quails and common pheasants.
abstract: The pharmacokinetics of enrofloxacin and marbofloxacin was studied in Japanese quails and common pheasants. Healthy mature birds from both species and both genders were treated intravenously and orally with enrofloxacin (10 mg/kg) and marbofloxacin (5 mg/kg). After intravenous administration enrofloxacin was extensively metabolised to ciprofloxacin. Metabolites of marbofloxacin were not detected. Values of volume of distribution were respectively 4.63 l/kg and 3.67 l/kg for enrofloxacin and 1.56 l/kg and 1.43 l/kg for marbofloxacin. In quails, total body clearance values were higher than those in pheasants and other avian species. After oral application enrofloxacin was rapidly absorbed in quails, more rapidly than marbofloxacin. Pheasants absorbed both antimicrobials at a lower rate. Higher bioavailability was observed for marbofloxacin (118%). Relatively low bioavailability was established in quails for enrofloxacin (26.4%), accompanied by extensive conversion to ciprofloxacin. Generally, quails absorbed and eliminated both fluoroquinolones more rapidly than pheasants; the latter showed pharmacokinetics similar to poultry. Because of favourable pharmacokinetic properties, marbofloxacin should be preferred for oral administration in Japanese quails and pheasants for treatment of infections caused by equally susceptible pathogens.
authors.affiliation: a Department of Pharmacology, Physiology of Animals and Physiological Chemistry, Faculty of Veterinary Medicine , Trakia University , Stara Zagora , Bulgaria.
authors.forename: L D
authors.initials: LD
authors.lastname: Lashev
authors.forename: D J
authors.initials: DJ
authors.lastname: Dimitrova
authors.forename: A
authors.initials: A
authors.lastname: Milanova
authors.forename: R G
authors.initials: RG
authors.lastname: Moutafchieva
mesh_terms: D061605:Administration, Intravenous / Q000662:veterinary; D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics*; D001682:Biological Availability; D002939:Ciprofloxacin / Q000378:metabolism; D003370:Coturnix / Q000378:metabolism; D000077422:Enrofloxacin; D005260:Female; D024841:Fluoroquinolones / Q000493:pharmacokinetics*; D046094:Galliformes / Q000378:metabolism*; D008297:Male
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D000077422:Enrofloxacin; D002939:Ciprofloxacin; C080260:marbofloxacin